دورية أكاديمية
Clinical application of a GPU-accelerated monte carlo dose verification for cyberknife M6 with Iris collimator
العنوان: | Clinical application of a GPU-accelerated monte carlo dose verification for cyberknife M6 with Iris collimator |
---|---|
المؤلفون: | Peng Zhou, Yankui Chang, Shijun Li, Jia Luo, Lin Lei, Yufen Shang, Xi Pei, Qiang Ren, Chuan Chen |
المصدر: | Radiation Oncology, Vol 19, Iss 1, Pp 1-13 (2024) |
بيانات النشر: | BMC, 2024. |
سنة النشر: | 2024 |
المجموعة: | LCC:Medical physics. Medical radiology. Nuclear medicine LCC:Neoplasms. Tumors. Oncology. Including cancer and carcinogens |
مصطلحات موضوعية: | GPU-accelerated Monte Carlo, CyberKnife, Patient-specific quality assurance, Medical physics. Medical radiology. Nuclear medicine, R895-920, Neoplasms. Tumors. Oncology. Including cancer and carcinogens, RC254-282 |
الوصف: | Abstract Purpose To apply an independent GPU-accelerated Monte Carlo (MC) dose verification for CyberKnife M6 with Iris collimator and evaluate the dose calculation accuracy of RayTracing (TPS-RT) algorithm and Monte Carlo (TPS-MC) algorithm in the Precision treatment planning system (TPS). Methods GPU-accelerated MC algorithm (ArcherQA-CK) was integrated into a commercial dose verification system, ArcherQA, to implement the patient-specific quality assurance in the CyberKnife M6 system. 30 clinical cases (10 cases in head, and 10 cases in chest, and 10 cases in abdomen) were collected in this study. For each case, three different dose calculation methods (TPS-MC, TPS-RT and ArcherQA-CK) were implemented based on the same treatment plan and compared with each other. For evaluation, the 3D global gamma analysis and dose parameters of the target volume and organs at risk (OARs) were analyzed comparatively. Results For gamma pass rates at the criterion of 2%/2 mm, the results were over 98.0% for TPS-MC vs.TPS-RT, TPS-MC vs. ArcherQA-CK and TPS-RT vs. ArcherQA-CK in head cases, 84.9% for TPS-MC vs.TPS-RT, 98.0% for TPS-MC vs. ArcherQA-CK and 83.3% for TPS-RT vs. ArcherQA-CK in chest cases, 98.2% for TPS-MC vs.TPS-RT, 99.4% for TPS-MC vs. ArcherQA-CK and 94.5% for TPS-RT vs. ArcherQA-CK in abdomen cases. For dose parameters of planning target volume (PTV) in chest cases, the deviations of TPS-RT vs. TPS-MC and ArcherQA-CK vs. TPS-MC had significant difference (P 0.05). ArcherQA-CK had less calculation time compared with TPS-MC (1.66 min vs. 65.11 min). Conclusions Our proposed MC dose engine (ArcherQA-CK) has a high degree of consistency with the Precision TPS-MC algorithm, which can quickly identify the calculation errors of TPS-RT algorithm for some chest cases. ArcherQA-CK can provide accurate patient-specific quality assurance in clinical practice. |
نوع الوثيقة: | article |
وصف الملف: | electronic resource |
اللغة: | English |
تدمد: | 1748-717X |
Relation: | https://doaj.org/toc/1748-717X |
DOI: | 10.1186/s13014-024-02446-1 |
URL الوصول: | https://doaj.org/article/c0e0c463ca414c1d9ab894e8ba4fb30e |
رقم الأكسشن: | edsdoj.0e0c463ca414c1d9ab894e8ba4fb30e |
قاعدة البيانات: | Directory of Open Access Journals |
تدمد: | 1748717X |
---|---|
DOI: | 10.1186/s13014-024-02446-1 |